SCHEMBL3173164

SCHEMBL3173164

CCCCCc1ccc(-c2ccc(-c3ccc4cc(OC(F)(F)F)ccc4c3)c(F)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.46
RARA P10276 2/20 0.46
RARG P13631 1/20 0.46
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
GRM2 Q14416 1/20 0.41
S1PR1 P21453 2/20 0.39
S1PR3 Q99500 2/20 0.39
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
FFAR4 Q5NUL3 4/20 0.37
FFAR1 O14842 2/20 0.37
CYP2C9 P11712 1/20 0.37
CACNA1C Q13936 1/20 0.37
FAAH O00519 1/20 0.37
THRB P10828 1/20 0.36
CHRM5 P08912 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3158114 0.97 ALOX5AP (0.43) RARBRARARARGALOX5APFEN1
SCHEMBL3170120 0.93 RARB (0.46) RARBRARARARGALOX5APFEN1
SCHEMBL3162030 0.93 RARB (0.46) RARBRARARARGALOX5APFEN1
SCHEMBL3161398 0.92 RARB (0.47) RARBRARARARGALOX5APFEN1
SCHEMBL3173929 0.92 ALOX5AP (0.45) RARBRARARARGALOX5APFEN1
SCHEMBL9276680 0.91 RARB (0.53) RARBRARARARGALOX5APFEN1
SCHEMBL3172809 0.91 RARB (0.45) RARBRARARARGFAAHTHRB
SCHEMBL3167483 0.91 RARB (0.45) RARBRARARARGFAAHTHRB
SCHEMBL6060009 0.90 RARB (0.47) RARBRARARARGALOX5APFEN1
SCHEMBL3158542 0.90 GRM2 (0.44) RARBRARARARGALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452514-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2010-03-31 EP disclosed
EP-1273562-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2009-07-22 EP disclosed
US-7145047-B2 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-12-05 US disclosed
EP-0952135-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2005-01-05 EP disclosed
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP disclosed
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-07-24 US disclosed
EP-1273562-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-01-08 EP disclosed
US-6468607-B1 MISCIBILITY, LARGE BIREFRINGENCE INDEX, NO STRONGLY POLAR GROUP IN ITS MOLECULE AND THUS CAN ALSO BE USED FOR ACTIVE MATRIX DRIVING, WIDE TEMPERATURE RANGE AND REQUIRES A HIGH SPEED RESPONSE AND A LOW VOLTAGE DRIVING DAINIPPON INK AND CHEMICALS, INC. (JP) 2002-10-22 US disclosed
EP-0952135-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same NLK, NOTCH1, NOTCH4 RARB 4021/4885RARA 3552/4885RARG 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.